ASBrS Proposes Including Cryoablation in Breast Cancer Guidelines
Event summary
- ASBrS is finalizing updated guidelines that include cryoablation for low-risk breast cancer in patients aged 70+ with tumors ≤1.5 cm.
- The proposed guidelines align with the FDA's October 2025 marketing authorization for cryoablation in breast cancer treatment.
- IceCure's ICE3 trial showed a 3.1% local recurrence rate within 5 years, comparable to lumpectomy.
- ProSense® addresses a U.S. patient population of approximately 200,000 women annually.
The big picture
The proposed ASBrS guidelines mark a significant step toward broader adoption of cryoablation as a standard-of-care treatment for low-risk breast cancer. This follows the FDA's marketing authorization, reflecting growing clinical evidence supporting the efficacy and safety of cryoablation. The shift toward minimally invasive procedures aligns with broader industry trends favoring less invasive, patient-friendly treatment options.
What we're watching
- Adoption Pace
- How quickly breast surgeons will recommend cryoablation following ASBrS guideline finalization.
- Reimbursement Expansion
- Whether the inclusion in guidelines will accelerate reimbursement coverage for cryoablation.
- Competitive Dynamics
- The pace at which other medical societies adopt similar guidelines for cryoablation.
Related topics